<DOC>
	<DOC>NCT01601002</DOC>
	<brief_summary>Patients with an episode of depression in late life prescribed mirtazapine recruited from a clinical sample will be monitored for weight and receive a blood test during their usual course of treatment to determine polymorphisms in a specific gene (LEPR) thought to affect weight gain.</brief_summary>
	<brief_title>LEPR Polymorphism Weight Gain by Mirtazapine in Late Life Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<criteria>patients older than 50 years meeting criteria for a diagnosis of major depressive disorder (DSM IV code 296.2x or 296.3x) as confirmed by a score &gt; 20 on the HAMD 24 items scale and a structured clinical interview using the SCID by a consultant psychiatrist Treatment resistant depression (as defined by failure to respond to â‰¥2 adequate antidepressant trials) Major depressive disorder with psychosis (296.x4) Those with depression who fulfill the chronic specifier (MDE for &gt;2 years) Significant Axis II pathology Previous trial with mirtazapine Concurrent antipsychotic usage Comorbid dementia (as confirmed by MMSE &lt; 24) Substance misuse including drug and/or alcohol dependence/abuse in the past 3 months Bipolar disorder Schizophrenia Obsessive compulsive disorder Post traumatic stress disorder Eating disorder Head injury Recent stroke (&lt; 3 months) Recent MI (&lt; 3 months) Currently actively participating in structured/formal psychotherapy Being non ambulatory Those actively suicidal Those incapable of informed consent</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Mirtazapine</keyword>
</DOC>